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Background: Cyclin-dependent kinase 4 (Cdk4) represents a
prime target for the treatment of cancer because most hu-
man cancers are characterized by overexpression of its ac-
tivating partner cyclin D1, loss of the natural Cdk4-specific
inhibitor p16, or mutation(s) in Cdk4’s catalytic subunit. All
of these can cause deregulated cell growth, resulting in tu-
mor formation. We sought to identify a small molecule that
could inhibit the kinase activity of Cdk4 in vitro and to then
ascertain the effects of that inhibitor on cell growth and
tumor volume in vivo. Methods: A triaminopyrimidine de-
rivative, CINK4 (a chemical inhibitor of Cdk4), was identi-
fied by screening for compounds that could inhibit Cdk4
enzyme activity in vitro. Kinase assays were performed on
diverse human Cdks and on other kinases that were ex-
pressed in and purified from insect cells to determine the
specificity of CINK4. Cell cycle effects of CINK4 on tumor
and normal cells were studied by flow cytometry, and
changes in phosphorylation of the retinoblastoma protein
(pRb), a substrate of Cdk4, were determined by western
blotting. The effect of the inhibitor on tumor growth in vivo
was studied by use of tumors established through xenografts
of HCT116 colon carcinoma cells in mice. Statistical tests
were two-sided. Results: CINK4 specifically inhibited Cdk4/
cyclin D1 in vitro. It caused growth arrest in tumor cells and
in normal cells and prevented pRb phosphorylation. CINK4
treatment resulted in statistically significantly (P = .031)
smaller mean tumor volumes in a mouse xenograft model.
Conclusions: Like p16, the natural inhibitor of Cdk4, CINK4
inhibits Cdk4 activity in vitro and slows tumor growth
in vivo. The specificity of CINK4 for Cdk4 raises the possi-
bility that this small molecule or one with a similar structure
could have therapeutic value. [J Natl Cancer Inst 2001;93:
436–46]
Progression through the cell cycle is regulated by the activity
of various cyclin-dependent kinases, their cyclin partners, and
cognate inhibitor proteins (1–6). Cyclin-dependent kinase 4
(Cdk4) is an important cell cycle kinase, since its activity is
required for initiating the phosphorylation of the retinoblastoma
protein (pRb). This triggers a cascade of events that compels
cells toward an irreversible commitment to proliferation (7–9).
In its hypophosphorylated form, pRb sequesters the E2F family
of transcription factors (10), which prevent cells from initiating
DNA synthesis. Hyperphosphorylation of pRb, which is initiated
by Cdk4 and completed by Cdk2 and Cdk6, releases the seques-
tered transcription factors, resulting in the loss of pRb’s growth-
inhibitory function (8), thus allowing cells to enter S phase.
The activity of Cdk4 is negatively regulated by p16INK4A,
hereafter referred to as p16, which acts by binding to Cdk4 and
preventing its association with cyclin D1 as well as the subse-
quent phosphorylation of pRb (6,11,12). p16 can thus be thought
of as preventing aberrant activation of Cdk4 under normal con-
ditions. When functional p16 is absent because of mutation,
deletion, or transcriptional silencing of the gene, cells undergo
unregulated proliferation that results in tumor formation (13,14).
Conversely, ectopic overexpression of p16 causes cells to arrest
in G1. This p16-mediated arrest is dependent on the presence of
functional pRb (11,15–17). It has been observed that there is a
natural inverse relationship between the presence of p16 and
pRb in more than 60% of human cancers (18,19). In tumors
deficient in p16, pRb is always present in an intact and func-
tional form. Unmutated p16 is usually present in tumors that lack
functional pRb. Moreover, the majority of human cancers have
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either constitutively activating mutations in Cdk4 that prevent
p16-mediated Cdk4 inhibition or inactivating mutations in p16
itself or they overexpress the Cdk4-activating partner cyclin D1
and/or have lost active pRb (5). These findings imply that de-
regulation of Cdk4 activity can cause the unrestricted cell
growth that results in tumor formation.
The link between Cdk4 activation and pRb phosphorylation
and the crucial role that this pathway plays in cell cycle pro-
gression makes Cdk4 an important therapeutic target in cancer.
It is conceivable that inhibition of Cdk4 would prevent unregu-
lated growth of cancer cells. That is, a Cdk4-specific inhibitor in
a p16-deficient, pRb-positive cell would prevent Cdk4 from
phosphorylating pRb, which would lead to a G1 block in the cell
cycle and thereby prevent cell proliferation. Like p16, the in-
hibitor would have no effect on pRb-deficient cells or on cells
that contain inactivated pRb.
Using a recently described screen that identifies novel small
molecule inhibitors of Cdk4 activity (20), we identified CINK4
(a chemical inhibitor of Cdk4) as a compound that specifically
inhibits Cdk4 in an in vitro enzyme assay. We have now tested
the efficacy of CINK4 as an inhibitor of cell growth in vitro by
treating tumor cell lines and in vivo by using an established
mouse tumor model.
MATERIALS AND METHODS
Identification of CINK4
A high throughput screen was used to monitor the in vitro phosphorylation of
pRb by human recombinant Cdk4/cyclin D1 enzyme purified from insect cells in
the presence or absence of compounds from a library of potential small molecule
inhibitors of Cdk4 (20). CINK4 is one such compound that inhibited pRb phos-
phorylation in this screen.
Chemistry
CINK4 was prepared in a three-step synthesis starting with 2,4,6-
trichloropyrimidine. All starting materials were obtained from Fluka (Buchs,
Switzerland). First, trans-4-amino-cyclohexanol (20.8 mL [0.15 mol]) was re-
acted in an ethanol solution (90 mL) with 2,4,6-trichloropyrimidine (17.17 mL
[0.15 mol]) in the presence of triethylamine (20.8 mL [0.15 mol]) at room
temperature for 5 hours to give a mixture of the 2- and 4-substituted regioisomers
of 4-(2,6-dichloro-pyrimidin-4-ylamino)-cyclohexanol. After chromatographic
separation on silica gel, 4-(2,6-dichloro-pyrimidin-4-ylamino)-cyclohexanol
(11.8 g [0.045 mol]) was treated with 1-benzyl-1H-indol-5-ylamine (8.9 g [0.04
mol]) and triethylamine (10 mL [0.072 mol]) in ethanol at 150 °C for 24 hours.
The resulting compound, 4-(2-[1-benzyl-1H-indol-5-ylamino]-6-chloro-
pyrimidin-4-ylamino)-cyclohexanol (7.0 g [0.016 mol]) was heated with aqueous
ethylamine (100 mL, 70% [1.25 mol]) in a sealed tube at 130 °C for 24 hours,
yielding yellowish crystals of CINK4 (melting point, 204 °C–205 °C). The
integrity and purity of the final compound and the intermediates were assessed
by nuclear magnetic resonance (NMR) spectroscopy (1H-, 13C NMR, nuclear
Overhauser effect) and mass spectrometric and combustion analyses. By these
criteria, the CINK4 used in this study was 100% pure.
Kinase Assays
The human cyclins A, B, E, D1, and D2 were co-expressed as glutathione
S-transferase (GST) fusion proteins in Sf9 insect cells with the Cdk catalytic
subunits (Cdks 1, 2, 4, and 6) as described previously (21–24). The holoen-
zymes, containing a Cdk bound to a GST cyclin, were purified by use of reduced
glutathione (GSH)–Sepharose (Amersham-Pharmacia, Zurich, Switzerland). The
human tyrosine kinases v-abl, c-met, IGF-1R, and Insulin-R were also expressed
as GST fusions in Sf9 cells and were purified over GSH–Sepharose exactly like
the Cdk holoenzymes. Kinase reactions were performed as described previously
(20,25–27) by use of purified tyrosine kinases or the recombinant cyclins com-
plexed with Cdk catalytic subunits in a 1 : 1 ratio in the presence and in the
absence of CINK4 by use of the radioactive label [33P]adenosine triphosphate
(ATP). GST-pRb(152) (Santa-Cruz Biotechnology, Santa Cruz, CA), which con-
tains the C-terminal 152 amino acid fragment of pRb, was used as a substrate for
all Cdk enzyme assays, whereas routinely used protein tyrosine kinase peptide
substrates that contain a unique tyrosine residue were used for the specific
tyrosine kinase assays (24–27). Kinase activity was detected and/or measured by
phosphorimage quantitation. All kinase assays were performed in duplicate and
represent an average of three independent experiments. Using 10 empirically
determined concentrations between 0 and 100 M of CINK4, we determined the
concentration of CINK4 that inhibited 50% of the activity of each kinase (IC50).
The IC50 was obtained by plotting the percentage of total radioactive counts
incorporated into the substrate by a kinase at a certain concentration of inhibitor
compared with total counts incorporated in the absence of CINK4 versus the
concentration of the inhibitor.
Interactive Modeling Studies
The modeling work was performed by use of MacroModel version 4.0 soft-
ware (28) to verify our observations in secondary in vitro enzyme assays that
CINK4 inhibits Cdk4 but not Cdk2. Our Cdk4 model is based on the published
coordinates of a Cdk2–ATP complex (29) that keeps the Cdk2 amino acid
residues within 6 &ARING; of any atom of ATP. We used the sequence align-
ments reported by Hanks and Quinn (30) to identify the amino acid residues that
differed between Cdk4 and Cdk2. Those residues in Cdk2 (Phe 82, Leu 83, His
84, Lys 89, and Gln 131) were then changed in the model to the analogous
residues in Cdk4 (His 95, Val 96, Asp 97, Thr 102, and Glu 144, respectively),
so that similar rotameric states for the amino acid side chains were maintained.
Interactive docking experiments were performed after ATP was removed from
the model and replaced with the structure of CINK4 to determine whether
CINK4 could compete with ATP for binding to Cdk4. The orientations of
CINK4 and Cdk4 shown in Fig. 1 were considered to be satisfactory because
of the strict overlap of the Cdk4/ATP and Cdk4/CINK4 coordinates. The result-
ing model was energy minimized to find the best nearby conformation [using
modified Assisted Model Building With Energy Refinement (AMBER*)
software (http://www.amber.ucsf.edu/amber/amber.html) force field with the
GB/SA solvation model (31,32)] by keeping the amino acids within the ATP-
binding site of Cdk4 rigid.
Cell Culture
All cells were cultured at 37 °C in 5% CO2 in medium supplemented with
10% fetal calf serum and 1% penicillin/streptomycin (both from Life Technolo-
gies, Inc. [GIBCO BRL], Rockville, MD). U2OS human osteosarcoma and
NIH3T3 mouse fibroblast cells were grown in Dulbecco’s modified Eagle
medium (DMEM) and high glucose (4500 mg/L) with stable glutamine
(AMIMED, Allschwil, Switzerland). MRC-5 human fibroblast cells were grown
in DMEM and low glucose (1000 mg/L) with stable glutamine (AMIMED).)
HCT116 human colon carcinoma cells were grown in McCoy’s 5A medium with
stable glutamine (AMIMED). U2OS and HCT116 cells lack p16 and express
functional pRb (pRb positive and p16 negative), whereas NIH3T3 and MRC-5
cells express functional pRb and p16 (pRb positive and p16 positive).
Exponentially growing cells, representing an asynchronous population, were
seeded at a density of 7.5 × 104 cells/mL in 10 mL of medium per T75 flask and
grown for 24 hours before being treated with CINK4. CINK4 was dissolved in
10% dimethyl sulfoxide (DMSO) to make 100× stock solutions and was added
to cells at final concentrations of 5 and 10 M. Cells were then incubated
for another 24 hours, after which they were harvested and washed once with
phosphate-buffered saline (PBS). For western blotting, the washed cells were
then frozen at –80 °C. For flow cytometry analyses, washed cells were fixed in
70% ethanol at −20 °C overnight and kept at −20 °C. For detection of apoptosis,
treated cells were harvested, washed with PBS, and fixed with 2% paraformal-
dehyde for 15 minutes on ice. Cells were washed again with PBS, fixed in 70%
ethanol at −20 °C overnight, and stored at −20 °C. All experiments were per-
formed at least twice under similar conditions to ensure reproducibility.
Quinidine and roscovitine were purchased from Sigma Chemical Co. (St.
Louis, MO), and 100× stock solutions of each were prepared in 10% DMSO.
Cells were treated with quinidine at a concentration of 50 M for 24 hours to
block them in the early G1 phase of the cell cycle. Serum-starved and mimosine-
treated cells were released in the presence of 10 M roscovitine.
Mimosine (CALBIOCHEM AG, Lucerne, Switzerland) was prepared as a
100× stock solution in 10% DMSO and was added to cells at a final concen-
tration of 0.2 mM. Cells were treated for 32 hours with mimosine, after which
they were washed and then released into fresh medium lacking mimosine in the
presence and absence of CINK4.
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MRC-5 and HCT116 cells were serum starved for 72 hours in medium con-
taining 0.1% serum, then released into 10% serum-containing medium with and
without 5 and 10 M CINK4 for 24 hours.
Immunoprecipitation of Cdk4/Cyclin D Complexes
A Cdk4 antibody (product number sc-260; Santa Cruz Biotechnology, Santa
Cruz, CA), immobilized on protein A–Sepharose beads, was used to immuno-
precipitate Cdk4-bound cyclin D complexes from CINK4-treated HCT116 cells.
Lysates were prepared by solubilizing cells in IP buffer (i.e., 25 mM Tris–HCl
[pH 7.5], 60 mM -glycerophosphate, 15 mM MgCl2, 15 mM EGTA, 0.1 mM
sodium fluoride, 15 mM p-nitrophenyl phosphate, 1 mM dithiothreitol, 0.1 mM
phenylmethylsulfonyl fluoride [PMSF], and 0.1% Nonidet P-40). Immunopre-
cipitations were carried out in IP buffer by use of equal amounts of total protein
(300 g). The beads were washed eight times with 1 mL of ice-cold IP buffer
and 1 mL of ice-cold wash buffer (50 mM Tris–HCl [pH 7.5], 10 mM MgCl2,
and 1 mM dithiothreitol) before being used for the in vitro Cdk4 kinase assay
(using pRb as substrate).
Cell Cycle Analysis
Cells fixed in 70% ethanol were centrifuged for 1 minute at 3000g at 25 °C,
washed once with PBS, treated with 3 mg/mL ribonuclease (Sigma Chemical
Co.) for 30 minutes at 37 °C, and stained with 50 g/mL propidium iodide
(Sigma Chemical Co.) for 1 hour at room temperature. Flow cytometry analyses
were performed on the Becton Dickinson fluorescence-activated cell sorter-
calibur (Becton Dickinson, Zurich, Switzerland) by use of the Becton Dickinson
Cell Quest program. Flow cytometry data were acquired with the use of linear
amplification of the fluorescence area measurement (FL-2) and pulse processing
(area versus width) to gate on single events, with the total event rate not ex-
ceeding 300 events/second. Data acquisition was set to stop after 9 minutes or
after a minimum of 10 000 events had been collected in the single-events region.
Apoptosis Detection Assay
The terminal deoxynucleotidyl transferase-mediated bromodeoxyuridine
(BrdU) triphosphate nick end-labeling (TUNEL) assay, which detects DNA
strand breaks, was performed with the use of the APO-BRDU kit (Phoenix Flow
Systems, San Diego, CA) according to manufacturer’s instructions to detect
apoptosis. Apoptosis was quantified by use of flow cytometry. We also used the
Cell Death Detection Enzyme-Linked Immunosorbent Assay kit (Roche Mo-
lecular Diagnostics, Basel, Switzerland), according to the manufacturer’s in-
structions to detect DNA fragmentation.
Western Blot Analyses
The frozen cell pellets were thawed and lysed in 100–200 L of RIPA buffer
(i.e., 25 mM Tris–HCl [pH 7.5], 1 mM EDTA, 50 mM NaCl, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 0.1% Tween 20, 50 mM
-glycerophosphate, 0.2 mM dithiothreitol, 2 mM sodium orthovanadate, 1 mM
PMSF, 10 g/mL Antipain, 10 g/mL Leupeptin, and 1× Complete™ Protease
inhibitors [Roche Molecular Diagnostics]) at 4 °C. The samples were centrifuged
for 15 minutes at 4 °C at 10 000 rpm. Protein concentrations of the resulting
supernatants were determined by use of the Bio-Rad Protein Assay (Bio-Rad,
Zurich, Switzerland). Equal amounts of protein (20 g) were separated on 7.5%
(for pRb western blots) and 12.5% (for Cdk4, cyclin D1, cdc2, and cyclin A
western blots) SDS–polyacrylamide gels and transferred to Immobilon-P Trans-
fer Membrane (Millipore Corp., Zurich, Switzerland). The membranes were
probed with the following primary antibodies: Cdk4-Ab (product number sc-260
from Santa Cruz Biotechnology) at 1 : 100 dilution to detect Cdk4; Ab-5 (prod-
uct number OP-66 from CALBIOCHEM AG) at 1 : 200 dilution to detect phos-
phorylated and unphosphorylated full-length pRb; C-15 (product number sc-50
from Santa Cruz Biotechnology) at 1 : 2000 dilution to detect the carboxy-
terminal 15 amino acids of pRb; Ser795 (New England Biolabs, Inc., Basel,
Switzerland) at 1 : 200 dilution to detect phosphorylation of pRb at serine residue
795; Ser780 (batch number SZ254 raised at Novartis, Basel, Switzerland) at
1 : 20 dilution to detect phosphorylation of pRb at serine residue 780; and P-Tyr-
100 (product number 9411 from New England Biolabs, Inc.) at 1 : 2000 dilution
to detect phosphorylation of tyrosine residue 15 in all Cdks. The secondary
antibody was horseradish peroxidase-conjugated anti-rabbit immunoglobulin G.
Bands were visualized by chemiluminescence by use of the ECL kit (Amersham-
Pharmacia, Zurich, Switzerland).
Detection of Senescence-Associated -Galactosidase
After 24 hours of treatment with CINK4, cells were washed with PBS, fixed
in 0.5% glutaraldehyde solution in water for 2 minutes, washed again in PBS,
and stained with X-gal solution (i.e., 1 mg/mL X-gal, 0.12 mM K3Fe[CN]6, 0.12
mM K4Fe[CN]6, and 1 mM MgCl2 in PBS [pH 6.0]) overnight at 37 °C. Pho-
tographs were taken after an overnight incubation at 37 °C with the staining
solution. All reagents were purchased from Sigma Chemical Co.
In Vivo CINK4 Experiments
The Ethical Committee of the Cantonese Veterina¨ramt of Basel Stadt ap-
proved all experimental protocols involving animals. Female BALB/c nu/nu
(nude) mice (19–21 g in body weight) were obtained from Iffa Credo
(L’Arbresle, France).
Adherent HCT116 cells were washed once with Hanks’ buffer (Life Tech-
nologies, Inc.), treated with 0.25% trypsin, washed again with Hanks’ buffer, and
adjusted to a final concentration of 1 × 107 viable cells/mL in Hanks’ buffer
based on trypan blue staining. This suspension (0.1 mL) was injected subcuta-
neously into each of 24 mice (eight mice per treatment group). Twenty days
later, when tumors derived from those cells had reached a volume of approxi-
mately 100 mm3, the actual tumor volumes were measured by use of calipers,
Fig. 1. Structure of CINK4 (a chemical inhibitor of
Cdk4) and its predicted mode of binding to Cdk4
(cyclin-dependent kinase 4). Structure and model
of the relative binding modes of CINK4 (yellow)
and adenosine triphosphate (ATP) (green) in the
ATP pocket of Cdk4 (gray). In this model, the
structures of CINK4 and ATP are superimposed to
facilitate comparison of their interactions with
Cdk4. Hydrogen bonds are indicated by thin
black lines.
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and those values were used to estimate tumor volume according to the formula:
volume (mm3)  length (mm) × width (mm2) × /6. The mice were then placed
into three groups containing eight mice each, the groups were randomly assigned
with respect to treatment, and treatment with CINK4, 5-fluorouracil, or control
was initiated. CINK4 was administered by intraperitoneal injection at a dose
of 30 mg/kg every 12 hours, while 5-fluorouracil (Roche Pharma Schweiz,
Reinach, Switzerland) was administered by intravenous injection into a lateral
tail vein at a dose of 75 mg/kg once per week. Mice in the control group received
the CINK4 diluent (5% DMSO, 0.05% Tween 80, and 95% physiologic saline)
by intraperitoneal injection. All treatments were administered at a constant vol-
ume (10 mL/kg) for 29 days. Tumor volumes were measured by a blinded
procedure at 2–4-day intervals throughout the treatment period. Body weights (in
g) were also measured at the same frequency. There was one death, which
occurred in the CINK4 treatment group, on the final day of the experiment.
Statistical Methods Used for Analyses of In Vivo Results
We determined the efficacy of various in vivo treatments by calculating the
change in tumor volume over time. Because changes in tumor volumes were not
always normally distributed, the data were logarithmically transformed to a
normal distribution. One-way analysis of variance (ANOVA) by use of Dun-
nett’s test was used to compare changes in tumor volumes in mice treated with
CINK4 or 5-fluorouracil with those in the control animals. The influence of
treatment on tumor growth rate was determined by comparing the slopes of a plot
of log tumor volume versus time from each mouse by one-way ANOVA by use
of the two-sided Student’s t–Newman–Keuls tests for multiple pairwise com-
parisons of all groups. The differences between final and initial body weights
were compared, by use of two-sided paired Student’s t tests, to determine that
these differences were distributed normally. For all tests, the level of significance
was set at P<.05. Note that, for these small sample sizes, the desired power level
of 0.8 was not always obtained. Statistical calculations were performed by use of
SigmaStat 2.03 (Jandel Scientific, San Rafael, CA). Statistical tests were two-
sided.
RESULTS
Selective Inhibition by CINK4
We identified CINK4 in a high throughput screen for small
molecules that could inhibit the phosphorylation of a pRb sub-
strate by Cdk4 (20). CINK4 was prepared subsequently in a
three-step synthesis that yielded a product that was 100% pure
(see the “Materials and Methods” section). To ascertain whether
the inhibitory activity of CINK4 was selective for Cdk4, we
determined the concentrations of CINK4 at which the activities
of five purified Cdks and four purified tyrosine kinases were
50% inhibited (IC50) by performing in vitro kinase assays in the
presence of increasing concentrations of CINK4 by use of pu-
rified peptides as substrates (26–29). As shown in Table 1,
CINK4 showed approximately fourfold more specificity toward
Cdk4/cyclin D1 than toward Cdk6/cyclin D1, as determined by
IC50s. Of interest, the concentrations of CINK4 required to in-
hibit the kinase activities of Cdk4 and Cdk6 when these kinases
were complexed with cyclin D2 were at least an order of mag-
nitude greater than those required to inhibit these kinases when
they were complexed with cyclin D1. This difference may re-
flect alterations in the three-dimensional structures of Cdks that
could result from the binding of different cyclins (3). The kinase
activity of Cdk2 complexed with either cyclin A or cyclin E was
not inhibited at CINK4 concentrations up to 100 M, while that
of Cdk5 complexed with p35 was inhibited by 25 M CINK4. In
contrast to these results, flavopiridol, another Cdk inhibitor that
is in phase III clinical trials, inhibits all Cdks to varying extents
(33). CINK4 did not substantially inhibit four prototypic tyro-
sine kinases (34), providing further evidence for the specificity
of CINK4 for Cdk4 (Table 1).
CINK4 and Molecular Modeling Studies
To confirm our experimental observations about the selectiv-
ity of CINK4 for Cdk4, we developed a hypothesis for the bind-
ing of CINK4 to Cdk4 that was based on interactive docking
experiments that modeled theoretical interactions between
CINK4 and Cdk4 (35). Because the structure of Cdk4 has not yet
been determined, we developed a theoretical model of its struc-
ture that was based on the x-ray crystal structure of the homolo-
gous enzyme Cdk2. Like ATP, CINK4 interacts with Cdk4 at
the ATP-binding pocket through hydrogen bonds with residues
Glu 94 and Val 96 within the Cdk4 kinase hinge region (Fig. 1).
According to this model, selective binding of CINK4 to Cdk4
may depend on its interactions with two Cdk4 residues, Thr 102
and Glu 144, which do not occur at comparable positions in
Cdk2. We assume that the phenyl group of the benzylic moiety
of CINK4 contacts Cdk4 through the side chain of Thr 102. A
similar contact with Cdk2, which contains a bulkier lysine resi-
due in the analogous position, would presumably be prevented
by steric hindrance. We also assume that the hydroxy group of
CINK4 donates a hydrogen bond to the carboxylate function
of Glu 144 in Cdk4. In contrast, the analogous residue in Cdk2
is a glutamine with a weaker potential to accept hydrogen bonds.
Further confirmation of our model for the CINK4–Cdk4 inter-
action comes from kinetic analysis, which indicates that CINK4
inhibits Cdk4 by competing with ATP for binding (data not
shown).
Effects of CINK4 on Asynchronous Cells
Results from the in vitro enzyme assays led us to believe that,
if CINK4 was a specific inhibitor of Cdk4, then it should block
growth of asynchronous cells in the G1 phase of the cell cycle.
We, therefore, tested the effects of CINK4 on two different
asynchronously growing cell lines: U2OS cells derived from a
human osteosarcoma, which lack p16 (p16 negative), and nor-
mal human fibroblast-derived MRC-5 cells, which express p16
(p16 positive). U2OS and MRC-5 cells, which both express
functional pRb (pRb positive), were treated with 5 and 10 M
CINK4 for 24 hours. These concentrations of CINK4 were used
because the concentrations of CINK4 that caused 50% inhibition
of growth of a large panel of cell lines were between 5 and 10
M (Soni R, Chaudhuri B: unpublished data). Flow cytometry
analyses of cells treated with CINK4 showed that both U2OS
and MRC-5 cells arrest in G1 of the cell cycle, as shown by an
Table 1. IC50* of CINK4 (a chemical inhibitor of cyclin-dependent kinase 4)
on various cyclin-dependent kinases and prototypic tyrosine kinases
Cyclin-dependent kinases
and other tyrosine kinases IC50 of CINK4, (M)
Cdk2/cyclin A >50
Cdk1/cyclin B >100
Cdk2/cyclin E >50
Cdk4/cyclin D1 1.5
Cdk4/cyclin D2 >50
Cdk6/cyclin D1 5.6
Cdk6/cyclin D2 >50
Cdk5/p35 25
v-abl >10
c-met >10
IGF-1R >10
Insulin-R >10
*IC50  the concentration of CINK4 that causes 50% inhibition of kinase
activity.
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increase in the G0–G1/S ratio (Fig. 2). However, the block at G1
was more profound in MRC-5 cells, which express the natural
inhibitor of Cdk4, p16. A similar G1 block was observed in
CINK4-treated HCT116 cells (p16 negative and pRb positive;
data not shown). The Cdk4 enzyme was immunoprecipitated
from CINK4-treated (5 and 10 M) HCT116 cells and its kinase
activity, as monitored by levels of pRb phosphorylation, were
substantially less than the kinase activity of Cdk4 enzyme im-
munoprecipitated from untreated cells (data not shown).
We also analyzed the effect of CINK4 treatment on phos-
phorylation of endogenous pRb, which is a natural substrate of
Cdk4. Treatment of U2OS and MRC-5 cells with 5 and 10 M
CINK4 reduced hyperphosphorylation of pRb, thereby presum-
ably maintaining pRb in an active state (Fig. 2; western blot
panels Ab-5 and C-15). CINK4 treatment also caused these cells
to incorporate less BrdU into their DNA (data not shown). This
result further suggested that pRb in the CINK4-treated cells had
undergone a reduction in hyperphosphorylation, because hyper-
phosphorylation of pRb is necessary for cells to enter S phase
and BrdU can be incorporated only when new DNA is synthe-
sized in S phase. Treatment of U2OS and MRC-5 cells with
CINK4 also reduced phosphorylation of pRb at serine residues
780 and 795, two sites that are specifically phosphorylated by
Cdk4 (23,36,37) (Fig. 2). We observed no changes in the levels
of Cdk4 in cells that were treated with either concentration of
CINK4 (Fig. 2). CINK4 treatment of the human colon carci-
noma cell line HCT116, which is p16 negative and pRb positive,
gave similar results (data not shown). These observations sug-
gest that CINK4 could function as an inhibitor of Cdk4 in these
cells.
Effects of CINK4 Following Serum Starvation and
Quinidine Block
Cdk4 is thought to be the first cyclin-dependent kinase that is
activated at the G1/S transition. Cdk4 activation initiates phos-
phorylation of pRb, which leads to a cascade of events that result
in the inactivation of pRb and entry of cells into S phase. The
transition from G0 (quiescence) to the G1 phase of the cell cycle
is dependent on serum growth factors: When cells undergo se-
rum starvation, they arrest at the G0/G1 boundary. When fresh
serum is added to such cells, they re-enter the cell cycle. We
hypothesized that, if CINK4 inhibits Cdk4 in vivo, serum-
starved cells should not re-enter the cell cycle when they are
exposed to fresh medium containing serum and CINK4. Flow
cytometric analyses showed that serum-deprived HCT116
(p16 negative and pRb positive) and MRC-5 (p16 positive and
pRb positive) cells remained arrested at G0 or G1 after they were
released into serum-containing medium containing 5 or 10 M
Fig. 2. Western blot and cell cycle analyses of asynchronous MRC-5 (top) and
U2OS cells (bottom) untreated (Control) and treated with 5 and 10 M CINK4
(a chemical inhibitor of cyclin-dependent kinase 4) for 24 hours. The western
blots in A and B, which were performed on the same cells that underwent cell
cycle analysis, were probed with antibodies to detect full-length phosphorylated
and unphosphorylated retinoblastoma protein (pRb) (Ab-5), full-length and N-
terminally truncated phosphorylated and unphosphorylated pRb (C-15), phos-
phorylation of pRb at serine residue 780 (Ser780), phosphorylation of pRb at
serine residue 795 (Ser795), and the catalytic subunit of the Cdk4 (Cdk4). In
each histogram, the y-axis corresponds to the cell number and the x-axis refers
to the FL-2 area. The cells in G0/G1 are represented by a peak at 200 on
the x-axis, the cells in G2 are represented by a peak at approximately 400, and
the area between those two peaks represents cells in S phase. The number in
the upper right corner of each histogram represents the ratio of cells in G1
phase to cells in S phase (G1/S ratio). A twofold (or greater) difference in G1/S
ratios between the untreated and CINK4-treated cells is taken as evidence of a
G1 arrest (66).
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CINK4 (Fig. 3, A and B). Western blot analyses showed that
treatment of the serum-deprived cells with CINK4 also inhibited
the phosphorylation of pRb at serine residues 780 and 795 that
normally occurs when serum-deprived cells are returned to se-
rum-containing medium (Fig. 3, A and B). Because Cdk4 has
been implicated as the kinase that specifically phosphorylates
these sites, these results provide further support that CINK4 acts
as a specific inhibitor of Cdk4 in these cells (23,36,37).
To further confirm that CINK4 prevents cells that are blocked
in early G1 from re-entering the cell cycle, we treated U2OS
Fig. 3. Effect of CINK4 (a chemical inhibitor of Cdk4)
on cell cycle progression and Cdk4 (cyclin-dependent
kinase 4) tyrosine phosphorylation. Western blot and
cell cycle analyses of serum-starved HCT116 (A) and
MRC-5 (B) cells. The cells were untreated (lane 1) or
cultured for 72 hours in medium containing 0.1% serum
(lane 2), then were transferred to medium containing
10% serum without (lane 3) or with 5 M CINK4 (lane
4) and 10 M CINK4 (lane 5) for 24 hours. The per-
centage of cells in G0/G1, S, and G2/M phases, deter-
mined by flow cytometry, are shown in the lower half of
each figure (Cell Cycle). The western blots, which were
performed on the same cells that underwent cell cycle
analysis, were probed with antibodies to detect full-
length phosphorylated and unphosphorylated retinoblas-
toma protein (pRb) (Ab-5), full-length and N-terminally
truncated phosphorylated and unphosphorylated pRb
(C-15), phosphorylation of pRb at serine residue 780
(Ser780), phosphorylation of pRb at serine residue 795
(Ser795), and the catalytic subunit of the Cdk4 (Cdk4).
C) Cell cycle analysis of U2OS cells. Cells were
untreated (Control) or treated with 50 M quinidine for
48 hours in medium containing 10% serum (50 M
quinidine 48 hours), then were transferred to medium
containing 10% serum without (Released) or with
(Released + 10 M CINK4) 10 M CINK4 for 24
hours. In all histograms, the y-axis corresponds to the
cell number and the x-axis refers to the FL-2 area. The
cells in G0/G1 are represented by a peak at 200 on
the x-axis, the cells in G2 are represented by a peak at
approximately 400, and the area between those two
peaks represents cells in S phase. The number in the
upper right corner refers to the G1/S ratio, while the
number in the lower corner refers to the percentage of
cells in S phase. Cells released from the quinidine block
in the presence of 10 M CINK4 do not enter the cell
cycle. D) Western blot analyses of Cdk4 that was im-
munoprecipitated from HCT116 cells, which were se-
rum starved for 72 hours (Ser-St) in medium containing
0.1% serum and then released into medium containing
10% serum without (Rel) and with 10 M roscovitine
(Rosco) (45) or 10 M CINK4 for 24 hours. Western
blots were probed with the same Cdk4 antibody (Cdk4-
Ab) used for immunopreciptation and with an antibody
(P-Tyr-100) that recognizes phosphorylated tyrosine on
proteins.
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cells with the potassium/sodium channel blocker quinidine for
24 hours to inhibit cell growth (38) and asked if CINK4 would
prevent these cells from entering the cell cycle when they were
released into fresh media lacking quinidine. Flow cytometry
analyses showed that U2OS cells that were released from a
quinidine block into medium containing 10 M CINK4 failed to
enter S phase, while cells released into medium lacking CINK4
did enter S phase (Fig. 3, C). Together, these cell culture results
support the hypothesis that CINK4 may act by inhibiting the
activity of Cdk4.
Effects of CINK4 on Cdk4 Tyrosine Phosphorylation
Dephosphorylation of tyrosine residue 15 in all Cdks acti-
vates these enzymes, and, in the specific case of Cdk4, allows
cells to progress through the cell division cycle. Conversely,
phosphorylation of this tyrosine residue in Cdk4 prevents serum-
starved, quiescent cells from re-entering the cell cycle, and the
presence of this phosphorylation is also required for G1 arrest
induced by UV irradiation (39,40). Fig. 3, D, shows that this
inhibitory tyrosine phosphorylation of Cdk4 was present in
serum-starved HCT116 cells. We then asked if CINK4 would
prevent dephosphorylation of Cdk4 when these cells were trans-
ferred to serum-containing medium to induce them to re-enter
the cell cycle. Fig. 3, D, shows that CINK4 treatment maintained
the tyrosine phosphorylation on Cdk4 on restimulation of serum-
starved HCT116 cells, whereas cells restimulated in the absence
of CINK4 lost the tyrosine phosphorylation and re-entered the
cell cycle. Roscovitine, by contrast, which inhibits Cdk2 at a
later time in G1 but not Cdk4 (41), failed to maintain tyrosine
phosphorylation of Cdk4 on restimulation of serum-starved
HCT116 cells (Fig. 3, D). This result strongly suggests that
CINK4 acts by inhibiting Cdk4.
Effects of CINK4 on S-Phase Progression
We predicted that, if CINK4 was a specific inhibitor of Cdk4
activity, treated cells would not be affected once they had en-
tered late G1 phase and had passed the point in the cell cycle at
which Cdk4 activity is required. To test this hypothesis, we
treated U2OS cells with mimosine, a nonprotein amino acid
from plants that inhibits eukaryotic DNA polymerase , to block
them at the G1/S boundary (42) and then released the cells from
the mimosine block by placing them in fresh medium that lacked
mimosine and either contained or lacked CINK4. We then de-
termined the cell cycle profiles at 16 and 38 hours after mimo-
sine was removed from the cells and found that neither 5 nor 10
M CINK4 prevented the cells from proceeding further in the
cell cycle (Table 2). Cells released in the presence of 5 M
CINK4 completed the cell cycle and then arrested at the follow-
ing G1 phase. However, cells released from the mimosine block
in the presence of 10 M CINK4 completed the cell cycle and
then died at the following G1 phase (Table 2). In contrast, mi-
mosine-blocked cells placed in fresh medium lacking mimosine
and containing the Cdk2-specific inhibitor roscovitine, which
blocks cells at the G1/S boundary, did not re-enter the cell cycle
(data not shown). These results suggest that CINK4 has little
effect on cell cycle progression once cells have entered the late
G1 phase and have proceeded beyond the point in the cell cycle
at which Cdk4 activity is required. Therefore, they further con-
firm the specificity of CINK4 as a Cdk4 inhibitor.
Effect of CINK4 on Induction of Senescence-Associated
Markers
Cdk4 inhibition by the Cdk4-specific inhibitory protein, p16,
induces senescence (43–46). Senescence resembles G0, a state
that is analogous to terminal differentiation. The induction of
senescence-associated markers, such as senescence-associated
-galactosidase (SA -gal), in various cancer and normal cells
by p16 thus involves inhibition of Cdk4. To determine if CINK4
mimics p16 in its ability to induce senescence, we asked if SA
-gal expression was induced in cells that lack functional p16
when they are treated with CINK4. U2OS cells treated with
5 and 10 M CINK4 for 24 and 48 hours were stained to detect
SA -gal activity (44). Approximately 25% of the cells treated
with 5 M CINK4 were strongly positive for SA -gal activity,
while 10% of the cells were weakly stained (data not shown). In
contrast, approximately 5% of the cells treated with 10 M
CINK4 for 24 hours expressed SA -gal activity, while longer
treatment resulted in considerable cell death. From these results,
we conclude that, like p16, Cdk4 inhibition by CINK4 can lead
to senescence or apoptosis, depending on the concentration of
the inhibitor.
Effects of Prolonged Treatment of Cells With 10 µM
CINK4
Prolonged treatment of U2OS cells with CINK4 resulted in
considerable cell death. To determine if the U2OS cells were
dying by apoptosis, we treated them with 5 and 10 M CINK4
for 48 hours and then subjected them to TUNEL analysis to
detect the DNA strand breaks that characterize apoptotic cell
death. Fig. 4 shows that a 48-hour treatment of U2OS cells with
5 M CINK4 had little effect on the induction of apoptosis,
whereas a 48-hour treatment with 10 M CINK4 resulted in
apoptosis in 83% of the cells. These results were qualitatively
confirmed by use of a second assay for apoptosis that detects
DNA fragmentation (data not shown). The majority of the apop-
totic cells were blocked in G1. Similar results were obtained by
treating HCT116 cells for extended times with 10 M CINK4
(data not shown). Our results suggest that a delicate balance
exists between senescence and apoptosis in U2OS and HCT116
cells that are treated with CINK4: Treatment at lower concen-
trations and for shorter times with this Cdk4 inhibitor causes
Table 2. Cell cycle analysis of mimosine-treated U2OS osteosarcoma cells*
Treatment
% Cells in different phases
of the cell cycle, %
G0/G1 S G2/M SubG1
Control 53.4 33.6 12.0 1
Mimosine (32 h) 73.7 21.0 4.5 0.8
Released (16 h) 17.2 33.0 47.6 2.2
Released, 5 M CINK4 (16 h) 16.7 29.5 41.0 12.8
Released, 10 M CINK4 (16 h) 20.7 39.2 18.3 21.8
Released (38 h) 39.6 23.1 32.3 5
Released, 5 M CINK4 (38 h) 34.8 20.6 31.4 13.2
Released, 10 M CINK4 (38 h) 14.3 15.8 13.9 56
*Cells were untreated (control) or treated with mimosine for 32 hours in 10%
serum-containing medium and released in the presence of 10% serum with and
without 5 and 10 M CINK4 (a chemical inhibitor of cyclin-dependent kinase 4)
for 16 and 38 hours. Flow cytometry was used to determine the percentage of
cells with a sub-G1 DNA content and those in the G0G1, S, and G2 /M phases of
the cell cycle.
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cells to initiate senescence, whereas prolonged treatment at
higher concentrations drives cells into apoptosis. Of interest,
p16, a natural Cdk4 inhibitor, behaves similarly in that it induces
senescence in some cases and apoptosis in others. This behavior
may be due to different levels of p16 being expressed in different
cellular contexts (47).
Effect of pRb on CINK4 Inhibition of Cdk4
The natural Cdk4 inhibitor, p16, mediates its growth-
inhibitory function via pRb. We, therefore, tested if CINK4
inhibition of Cdk4 was also dependent on functional pRb. For
these studies, we used two pairs of cell lines that differed from
each other in the means by which pRb was functionally inacti-
vated. The first pair of cell lines consisted of mouse NIH3T3
cells (48), which have functional pRb (pRb positive), and a
congenic cell line that contains a homozygous deletion of pRb
(pRb negative); the second pair consisted of U2OS cells and
U2OS-TAg, a U2OS-derived cell line that was stably trans-
formed with simian virus 40 large T antigen (49), which func-
tionally inactivates pRb. Thus, U2OS cells are pRb positive and
p16 negative, while U2OS-TAg cells are pRb negative and p16
negative. CINK4 treatment caused a cell cycle block in NIH3T3
pRb-positive cells, while the congenic pRb-negative cells were
unaffected (Table 3). Similarly, U2OS cells (pRb positive) ar-
rested in G1 on treatment with CINK4, while the U2OS-TAg
cells (pRb negative) did not. These results suggest that Cdk4
inhibition by CINK4 requires the presence of functional pRb.
Fig. 4. Induction of apoptosis on prolonged treatment of U2OS cells with 10 M
CINK4 (a chemical inhibitor of cyclin-dependent kinase 4) (48 hours). The top
row shows fluorescence intensity of a fluorescein isothiocyanate (FITC)-labeled
antibody to terminal deoxynucleotidyl transferase-mediated bromodeoxyuridine,
which is a measure of DNA fragmentation, plotted as a function of total DNA
content. An intensity of less than 101 corresponds to cells with intact DNA, while
an intensity of greater than 101 corresponds to cells with fragmented DNA
(apoptotic cells). The bottom row shows the number of cells plotted as a func-
tion of FITC fluorescence intensity (a measure of fragmented DNA). A shift of
the peak to higher fluorescence intensity corresponds to an increase in DNA
fragmentation.
Table 3. Functional retinoblastoma protein (pRb) is required for CINK4
(chemical inhibitor of cyclin-dependent kinase 4)-mediated growth arrest*
Cells Treatment† pRb status‡
% of cells in
G0 /G1 : S ratio§G0 /G1 S
NIH3T3 Control + 44.7 12.2 3.7
− 43.5 20.0 2.2
5 M CINK4 + 92.3 3.2 29.0
− 49.8 9.1 5.5
10 M CINK4 + 88.4 3.1 28.3
− 48.7 11.6 4.2
U2OS¶ Control + 49.8 19.9 2.5
− 42.5 30.3 1.4
5 M CINK4 + 79.5 11.0 7.2
− 44.8 26.3 1.7
10 M CINK4 + 82.9 3.6 23.1
− 42.8 25.1 1.7
*Cell cycle analyses of NIH3T3 mouse fibroblast cells and U2OS human
osteosarcoma cells as determined by flow cytometry.
†Control  untreated cells; 5 and 10 M CINK4 treatments were for 24
hours.
‡+  cells express functional pRb; −  cells do not express functional pRb.
§The G0 /G1 : S ratio is a measure of the percentage of cells blocked in G1.
NIH3T3 cells normally express both p16 and pRb (p16positive and pRb positive).
A congenic cell line that contains a homozygous deletion of the retinoblastoma
gene and, therefore, lacks functional pRb (p16positive and pRbnegative) was used to
test the effect of pRb on CINK4-mediated growth arrest.
¶U2OS cells lack p16 but normally express pRb (p16negative and pRbpositive).
U2OS-TAg, a U2OS-derived cell line that was stably transformed with simian
virus 40 large T antigen (49), which functionally inactivates pRb (p16negative and
pRbnegative), was used to test the effect of pRb on CINK4-mediated growth arrest.
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This again indicates that, like p16, CINK4 requires pRb to mani-
fest its action.
Effect of CINK4 on Established Tumors
We tested the efficacy of CINK4 as a Cdk4 inhibitor in a
mouse xenograft model by using tumors derived from human
HCT116 colon carcinoma cells. Initial pharmacokinetic experi-
ments indicated that administration of CINK4 at 30 mg/kg in-
traperitoneally every 12 hours was sufficient to maintain the
concentration of CINK4 in the tumors greater than 0.5 M, a
concentration that was necessary to inhibit the growth of those
cells in vitro by 50% (data not shown). CINK4 treatment was
initiated 20 days after the subcutaneous injection of HCT116
cells into nude mice, when the tumors had a volume of approxi-
mately 100 mm3, and was continued for 29 days.
Fig. 5 shows that, after 29 days of treatment, CINK4 resulted
in a statistically significant (P  .031) smaller final tumor vol-
ume (586 mm3; 95% confidence interval [CI]  383 to 789
mm3) compared with tumors in mice treated with vehicle control
(1088 mm3; 95% CI  611 to 1565 mm3). However, mice
treated for the same length of time with 5-fluorouracil had an
even greater reduction in final tumor volume (to 327 mm3; 95%
CI  175 to 479 mm3). Although CINK4 treatment slowed
tumor growth rates by approximately 17% compared with treat-
ment with vehicle control, this reduction in growth rate failed to
reach statistical significance by the Dunnett test (P  .1) but
was statistically significant as determined by the less conserva-
tive Student’s t–Newman–Keuls tests (P  .028). 5-Fluoroura-
cil had a more dramatic effect, showing an approximately 60%
reduction in tumor growth rate compared with controls or
CINK4 (P<.001 for both) (Fig. 5, inset). The mice appeared to
tolerate both the CINK4 and the 5-fluorouracil treatments, de-
spite experiencing an approximately 20% reduction in body
weight during the course of those treatments. A second indepen-
dent experiment, which resulted in mean final tumor volumes of
960 mm3 (95% CI  639 to 1281 mm3) for controls, 598 mm3
(95% CI  343 to 853 mm3) for CINK4 treatment, and 280
mm3 (95% CI  203 to 357 mm3) for 5-fluorouracil treatment,
confirmed the in vivo antitumor activity of CINK4 against
HCT116-derived tumors (P  .035 for both treatment groups
versus controls as analyzed by the Dunnett test). Thus, CINK4
treatment was effective in vivo in inhibiting the growth of tu-
mors derived from cells that lack p16 but possess functional
pRb.
DISCUSSION
We show here that CINK4, a triaminopyrimidine derivative,
specifically inhibits Cdk4 in an in vitro kinase assay and reduces
tumor volume in a mouse model. Cdk4 is the key kinase that, by
phosphorylating pRb, is required for cell cycle entry and for
cells to emerge from quiescence (40,50). It should be noted that,
in some systems, the activities of Cdk4 and Cdk6 may be re-
sponsible for only a component of the phosphorylation of pRb
and that hyperphosphorylation of pRb, which is necessary for its
growth-inhibitory effects, requires subsequent phosphorylations
by Cdk2 (51). However, initial phosphorylation by Cdk4 and
Cdk6 may nevertheless be required for later Cdk2-mediated ac-
tions.
Most human tumors have alterations in the p16/Cdk4/pRb
pathway. Tumors deficient in p16 grow unabatedly, presumably
because Cdk4 is constitutively active in the absence of its natural
inhibitor. Therefore, inhibiting Cdk4 activity in tumors that lack
Fig. 5. Effect of CINK4 (a chemical inhibitor of cyclin-dependent kinase 4) on
the volume of xenograft tumors derived from HCT116 human colon carcinoma
cells. Mice bearing tumors derived from the injection of HCT116 cells were
treated with vehicle controls (5% dimethyl sulfoxide/0.05% Tween 80/95%
physiologic saline), 5-fluorouracil (75 mg/kg, once per week, by intravenous
injection), or CINK4 (30 mg/kg, every 12 hours, by intraperitoneal injection)
starting on day 21 after injection of HCT116 cells. Panel A: tumor volumes over
time. The y-axis shows tumor volumes (in median mm3), and the x-axis shows
the number of days after HCT116 cells were injected into the mice. The inset
shows the tumor volume data plotted on a logarithmic scale. The growth rates
(slopes) of tumors from control mice (0.0346 ± 0.00219 SEM) were greater than
those of tumors from CINK4-treated (0.0287 ± 0.00106 SEM; P  .028) or
5-fluorouracil-treated (0.0138 ± 0.00182 SEM; P<.001) mice (by use of the
Student’s t–Newman–Keuls tests). Panel B: body weights over time. The y axis
shows body weights (in mean grams), and the x-axis shows the number of days
after HCT116 cells were injected into the mice. In both graphs, the filled circles
represent mice treated with vehicle controls, the unfilled circles represent treat-
ment with CINK4, and the filled inverted triangles represent 5-fluorouracil
treatment. Bars  95% confidence intervals. SEM  standard error of the
mean.
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p16 is essential to stop cell proliferation. CINK4 meets this
criterion: It replaces the activity of p16 in cells that lack p16 by
inhibiting Cdk4, most likely through direct binding to the ATP-
binding pocket of the kinase. Consistent with its in vitro inhi-
bition of Cdk4, CINK4 arrested the growth of asynchronous
MRC-5 and U2OS cells with concomitant loss of Ser780 and
Ser795 phosphorylations in the endogenous Cdk4 substrate,
pRb. However, normal diploid fibroblast MRC-5 cells resumed
the cell cycle after CINK4 was removed, while U2OS cells
treated in a similar fashion underwent appreciable cell death
(data not shown). CINK4 prevented cell cycle re-entry not only
of serum-starved MRC-5 and HCT116 cells but also of U2OS
cells after release from quinidine block, further suggesting in-
hibition of Cdk4 by CINK4. CINK4, however, had little effect
on progression through S phase (Table 2). Moreover, Cdk4
immunoprecipitated from CINK4-treated HCT116 cells had
statistically significantly less kinase activity than did Cdk4
immunoprecipitated from untreated cells, presumably because
the activity of the kinase in the treated cells was inhibited by
CINK4. These biochemical observations indicate that CINK4
prevents Cdk4 from phosphorylating pRb, thereby abolishing
entry of quiescent G0 cells into the cell cycle. Although p16
and its derived peptides have been shown to behave similarly
to each other (52–57), the precise physiologic role of p16 re-
mains unclear. Nevertheless, our results with CINK4, which
mostly parallel those that have been published with p16, suggest
that CINK4-mediated prevention of pRb phosphorylation and
inhibition of cell growth are a consequence of Cdk4 inhibition
(52–57).
It has been reported that cellular accumulation of p16 induces
senescence (43–45,58). Of interest, treatment of cells with 5 M
CINK4 also induced expression of a senescence-associated
marker, SA -gal, suggesting that induction of senescence in
both cases could be due to the inhibition of Cdk4. However,
senescence was “bypassed” when cells either were treated with
a higher concentration of CINK4 (10 M) or were exposed for
a prolonged period (48 hours) to 5 M CINK4, both of which
caused cells to undergo apoptosis. Ectopic expression of the
endogenous Cdk4 inhibitor p16 produces similar results (45,47).
These observations suggest that the phenomena of senescence
and apoptosis may be linked and that the extent of Cdk4 inhi-
bition may determine whether cells enter into senescence or
apoptosis. This possibility warrants further research to identify
gene(s) that are deregulated by Cdk4 inhibition per se and that
play a role in senescence and/or apoptosis.
A plethora of synthetic Cdk inhibitors have been described in
the literature (28,59–62) that inhibit either both Cdk2 and Cdk4
or all Cdks nonspecifically. A model for a synthetic tumor sup-
pressor molecule based on the cyclin-dependent kinase inhibi-
tory domain of the INK4 family has also been described, sug-
gesting the importance of Cdk4 inhibition in blocking tumor
growth (63). It was reported recently that certain diaminothia-
zole derivatives could act as selective inhibitors of Cdk4 (64).
CINK4 is among this emerging class of small molecule inhibi-
tors that are unique in their selectivity for Cdk4. Our demon-
stration that CINK4 drastically reduces tumor volume in an in
vivo mouse model suggests that CINK4 or compounds with
similar structures could have important clinical value for treating
tumors that either lack p16 (e.g., non-small-cell lung carcino-
mas) or contain deregulated Cdk4 activity [e.g., hepatoblastomas
(65)]. Our results also suggest that CINK4 could be useful for
studying aspects of cell growth and differentiation linked to
senescence and apoptosis, especially in cells lacking p16 but
possessing functional pRb.
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